Getting Help > Clinical Trials > Indiana

8-week randomized, double blind, placebo controlled trial of seroquel SR
University Hospital Outpatient Center, Indianapolis

Principal Investigator: Andrew W. Goddard, MD, Indiana University

Description of Study: The primary objective of this study is to test the hypothesis that a SSRI plus quetiapine SR (Seroquel SR) will result in superior early (first 1-3 weeks of treatment) stabilization of panic symptoms in SSRI-resistant, comorbid panic disorder patients versus a SSRI plus placebo. If accepted into the study, the patient will receive physicals, psychiatric exams, ECG, and study medication at no cost to the patient. There should be a total of 10 visits over 3 months and $15 will be given to the patient for each completed visit at the end of the study.

Eligibility Criteria:
- Provision of written informed consent
- Diagnosis of panic disorder with agoraphobia.
- Age 18-65 and in good physical health
- Currently receiving SSRI for panic attacks
- Comorbid major depression, dysthymia, or other anxiety disorders are eligible to participate.

Exclusion Criteria:
- Substance or alcohol dependence
- Pregnant or nursing
- Diagnosis of psychotic or bipolar disorder
- History of seizure disorder
- Axis II that would impair study visits
- Type I or Type II Diabetes

Study End Date: January 2010

Contact: Study Coordinator Carla E. Medlock, BA, (317) 274-0314 or cemedlock@iupui.edu

Website: www.clinicaltrials.gov, identifier: NCT00619892